Viridian Therapeutics (NASDAQ:VRDN) PT Raised to $40.00

Viridian Therapeutics (NASDAQ:VRDN – Get Rating) had its price objective increased by stock analysts at HC Wainwright from $35.00 to $40.00 in a note issued to investors on Thursday, The Fly reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 40.80% from the stock’s previous close.

A number of other equities analysts also recently commented on the stock. JMP Securities reduced their price objective on shares of Viridian Therapeutics from $47.00 to $46.00 and set a “market outperform” rating for the company in a research note on Tuesday, November 15th. Credit Suisse Group started coverage on Viridian Therapeutics in a research report on Friday, December 16th. They set an “outperform” rating and a $51.00 price target on the stock. B. Riley upped their price target on Viridian Therapeutics from $40.00 to $46.00 in a research report on Tuesday, January 10th. Cowen began coverage on Viridian Therapeutics in a research report on Monday, December 19th. They set an “outperform” rating on the stock. Finally, Needham & Company LLC began coverage on Viridian Therapeutics in a research report on Monday, December 19th. They issued a “buy” rating and a $45.00 target price on the stock. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $45.10.

Viridian Therapeutics Stock Down 3.1 %

Shares of NASDAQ VRDN opened at $28.41 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 17.35 and a current ratio of 17.35. The firm has a market capitalization of $808.55 million, a price-to-earnings ratio of -7.05 and a beta of 0.95. The stock has a 50 day moving average price of $33.72 and a 200 day moving average price of $26.58. Viridian Therapeutics has a 52-week low of $9.47 and a 52-week high of $39.00.

Viridian Therapeutics (NASDAQ:VRDN – Get Rating) last announced its quarterly earnings results on Wednesday, March 8th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.41). The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.46 million. Viridian Therapeutics had a negative net margin of 7,329.23% and a negative return on equity of 108.29%. The firm’s revenue for the quarter was down 50.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.32) EPS. Sell-side analysts expect that Viridian Therapeutics will post -3.33 earnings per share for the current year.

Insider Buying and Selling at Viridian Therapeutics

In other Viridian Therapeutics news, General Counsel Lara Meisner sold 1,297 shares of the company’s stock in a transaction on Friday, December 16th. The shares were sold at an average price of $28.44, for a total value of $36,886.68. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, General Counsel Lara Meisner sold 1,297 shares of the stock in a transaction dated Friday, December 16th. The shares were sold at an average price of $28.44, for a total transaction of $36,886.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Barrett Katz sold 47,377 shares of the stock in a transaction dated Tuesday, January 10th. The stock was sold at an average price of $35.30, for a total transaction of $1,672,408.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 181,344 shares of company stock valued at $6,216,752. 4.48% of the stock is owned by insiders.

Institutional Investors Weigh In On Viridian Therapeutics

Hedge funds have recently modified their holdings of the company. Metropolitan Life Insurance Co NY lifted its stake in Viridian Therapeutics by 47.0% in the 4th quarter. Metropolitan Life Insurance Co NY now owns 2,340 shares of the company’s stock valued at $68,000 after buying an additional 748 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Viridian Therapeutics in the 3rd quarter valued at about $77,000. Silverarc Capital Management LLC purchased a new position in Viridian Therapeutics in the 4th quarter valued at about $88,000. Legal & General Group Plc acquired a new stake in Viridian Therapeutics in the 2nd quarter valued at about $94,000. Finally, State Board of Administration of Florida Retirement System acquired a new stake in Viridian Therapeutics in the 2nd quarter valued at about $128,000.

Viridian Therapeutics Company Profile

(Get Rating)

Viridian Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis.